These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28133055)

  • 1. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
    Ishii N; Fujimori T; Kasagawa T; Udagawa I
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
    Assi H; Murray J; Boyle L; Rayson D
    Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
    Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
    Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres.
    Mullard AP; Misra V; Sumra P; Ali Z; O'Reilly SM; Malik Z
    Support Care Cancer; 2014 Aug; 22(8):2033-7. PubMed ID: 24595405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of Next-Day Administration of Pegfilgrastim after FEC100 Chemotherapy in Japanese with Breast Cancer on Neutrophil Count].
    Fujiwara D; Mashimo K; Kimura K; Noda A; Taki K; Yoshibayashi H; Takeda T; Tsubaki M; Nishida S; Sakaguchi K
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):149-152. PubMed ID: 28223672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
    Ishikawa T; Sakamaki K; Narui K; Nishimura H; Sangai T; Tamaki K; Hasegawa Y; Watanabe KI; Suganuma N; Michishita S; Sugae S; Aihara T; Tsugawa K; Kaise H; Taira N; Mukai H;
    Breast; 2021 Apr; 56():70-77. PubMed ID: 33631458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
    Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
    Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
    Fernandes R; Mazzarello S; Stober C; Ibrahim MFK; Dudani S; Perdrizet K; Majeed H; Vandermeer L; Shorr R; Hutton B; Fergusson D; Gyawali B; Clemons M
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.